ERBB2 and neoplasm: As monotherapy, rHER2 ECD mRNA-LNPs induced high anti-HER2 antibody titers, polyfunctional CD8<sup>+</sup> T cells (IFNγ<sup>+</sup>/TNFα<sup>+</sup>), and durable memory T cells, achieving 87.0% tumor inhibition.